Abstract
We report a case of primary esophageal CD30+/ALK+/MUM1+ anaplastic large cell lymphoma (ALCL) and discuss its diagnosis and treatment, specifically in regard to the unusual expression of the B cell marker, MUM1. A 29-year-old Mexican male presented with an esophageal mass with stenosis and dysphagia. Endoscopic samples were sent for hematoxylin–eosin staining and immunohistochemical analysis. Pathologic and immunohistochemical examination resulted in a diagnosis of primary ALCL of the esophagus with CD30+/ALK+/MUM1+ phenotype. This diagnosis was confirmed by molecular analysis [fluorescence in situ hybridization (FISH)]. Initially, two cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy were given, but the patient exhibited progressive disease. Subsequent treatment consisted of four cycles of ifosfamide, carboplatin, and etoposide (ICE). As of the 12-month follow-up examination, the patient is in complete remission. This case suggests that ALCL of the esophagus should be considered in the differential diagnosis of esophageal neoplasms. Biopsy through esophagoscopy or surgical exploration is recommended, and treatment with chemotherapy or radiotherapy can achieve long-term survival.
Similar content being viewed by others
References
Falini B, Pileri S, Zinzani PL, Carbone A, Zagonel V, Wolf-Peeters C, et al. ALK+ lymphoma: clinico-pathological findings and outcome. Blood. 1999;93(8):2697–706.
Falini B, Bigerna B, Fizzotti M, Pulford K, Pileri SA, Delsol G, et al. ALK expression defines a distinct group of T/null lymphomas (“ALK Lymphomas”) with a wide morphological spectrum. Am J Pathol. 1998;153:875.
Wu N, Pang L, Chen Z, Wang Y, Ma Q, Chen G, et al. Primary esophageal CD30-positive ALK-positive anaplastic large cell lymphoma: a case report and literature review. J Gastrointest Cancer. 2011;42(1):57–60.
Chan JK, Banks PM, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, et al. A revised European-American classification of lymphoid neoplasm proposed by the International Lymphoma Study Group: a summary version. Am J Clin Pathol. 1995;103:543–60.
Dawson IMP, Cornes JS, Morson BC. Primary malignant tumours of the intestinal tract. Br J Surg. 1961;49:80–9.
Matsuura H, Saito R, Nakajima S, Yoshihara W, Enomoto T. Non-Hodgkin lymphoma of the esophagus. Am J Gastroenterol. 1985;80:941–6.
Nagrani M, Lavine BC, Siskind BN, Knisley RE, Traube M. Primary non-Hodgkin lymphoma of the esophagus. Arch Intern Med. 1989;149:193–5.
Mengoli M, Marchi M, Rota E, Bertolotti M, Gollini C, Signorelli S, et al. Primary non-Hodgkin lymphoma of the esophagus. Am J Gastroenterol. 1990;85:737–41.
Maipang T, Panjapiyakul C, Sriplung H. Primary lymphoma of the esophagus: a case report. J Med Assoc Thai. 1992;75:299–303.
Tsukada T, Ohno T, Kihira H, Taniguchi M, Takahashi T, Arima S, et al. Primary oesophageal non-Hodgkin lymphoma. Intern Med. 1992;31:569–72.
Hosaka S, Nakamura N, Akamatsu T, Fujisawa T, Ogiwara Y, Kiyosawa K, et al. A case of primary low-grade mucosa associated lymphoid tissue (MALT) lymphoma of the esophagus. Gut. 2002;51:281–4.
Gupta NM, Goenka MK, Jindal A, Behera A, Vaiphei K. Primary lymphoma of the esophagus. J Clin Gastroenterol. 1996;23:203–6.
Yaakup H, Sagap I, Fadilah SAW. Primary oesophageal Ki (CD30)-positive ALK+ anaplastic large cell lymphoma of T-cell phenotype. Singapore Med J. 2008;49(10):e289.
Shiota M, Nakamura S, Ichinohasama R, Abe M, Akagi T, Takeshita M, et al. Anaplastic large cell lymphomas expressing the chimeric protein p80 NPM/ALK: a distinct clinicopathology entity. Blood. 1995;86:1954–60.
Wasco MJ, Fullen D, Su L, Ma L. The expression of MUM1 in cutaneous T-cell lymphoproliferative disorders. Hum Pathol. 2008;39(4):557–63.
Dearden CE, Johnson R, Pettengell R, Devereux S, Cwynarski K, Whittaker S, et al. Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma). Br J Haematol. 2011;153(4):451–85. doi:10.1111/j.1365-2141.2011.08651.x.Epub2011Apr11.
Falini B, Pileri S, Zinzani PL, Carbone A, Zagonel V, Wolf-Peeters, et al. ALK+ lymphoma: clinico-pathological findings and outcome. Blood. 1999;93:2697–706.
Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM. ALK− anaplastic largecell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral TCell Lymphoma Project. Blood. 2008;111:5496–504.
Blystad AK, Enblad G, Kvaloy S, Berglund A, Delabie J, Holte H, et al. High dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas. Bone Marrow Transplant. 2001;27:711–6.
Conflict of interest
We have no conflicts of interest to declare.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lino-Silva, L.S., Salcedo-Hernández, R.A., Molina-Frías, E. et al. Primary esophageal CD30-positive ALK-positive anaplastic large cell lymphoma with MUM1 expression. Esophagus 10, 51–54 (2013). https://doi.org/10.1007/s10388-012-0347-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10388-012-0347-3